Literature DB >> 15120664

What is the effect of systemic anticancer treatment on cognitive function?

Alessandro Minisini1, Gul Atalay, Andrew Bottomley, Fabio Puglisi, Martine Piccart, Laura Biganzoli.   

Abstract

Treatment regimens for solid tumours have been extensively investigated for their physical toxic effects, but far less is known about the potential impairment of cognitive function by anticancer treatment regimens. Here, we review published studies that examined cognitive function in adult patients receiving systemic therapy for solid tumours. Our review suggests that patients can experience cognitive changes related to their treatment. However, several studies had methodological limitations, such as use of a limited sample size, lack of baseline assessment, and lack of control for potential confounding factors. Better designed clinical trials are required so that the difficulties patients face in terms of reduced cognitive function as a result of anticancer treatment can be fully elucidated. These trials should have sufficient statistical power and, importantly, should also be prospective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120664     DOI: 10.1016/S1470-2045(04)01465-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  27 in total

Review 1.  Who benefits from psychosocial interventions in oncology? A systematic review of psychological moderators of treatment outcome.

Authors:  Rie Tamagawa; Sheila Garland; Marcus Vaska; Linda E Carlson
Journal:  J Behav Med       Date:  2012-01-22

Review 2.  Memory and cancer: a review of the literature.

Authors:  Graham J McDougall; JoAnn S Oliver; Forrest Scogin
Journal:  Arch Psychiatr Nurs       Date:  2014-03-22       Impact factor: 2.218

3.  Breast cancer morbidity: questionnaire survey of patients on the long term effects of disease and adjuvant therapy.

Authors:  Stefan Feiten; Jan Dünnebacke; Jochen Heymanns; Hubert Köppler; Jörg Thomalla; Christoph van Roye; Diana Wey; Rudolf Weide
Journal:  Dtsch Arztebl Int       Date:  2014-08-04       Impact factor: 5.594

4.  Long-term cognitive impairment in older adult twins discordant for gynecologic cancer treatment.

Authors:  Keiko Kurita; Beth E Meyerowitz; Per Hall; Margaret Gatz
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-08-22       Impact factor: 6.053

5.  Activity limitation and participation restrictions of breast cancer patients receiving chemotherapy: psychometric properties and validation of the Chinese version of the WHODAS 2.0.

Authors:  Hai Ping Zhao; Ying Liu; Hong Li Li; Li Ma; Yan Jun Zhang; Jing Wang
Journal:  Qual Life Res       Date:  2012-06-09       Impact factor: 4.147

6.  Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy.

Authors:  Robert J Ferguson; Brenna C McDonald; Andrew J Saykin; Tim A Ahles
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

7.  The utility of parent report in the assessment of working memory among childhood brain tumor survivors.

Authors:  Robyn A Howarth; Jason M Ashford; Thomas E Merchant; Robert J Ogg; Victor Santana; Shengjie Wu; Xiaoping Xiong; Heather M Conklin
Journal:  J Int Neuropsychol Soc       Date:  2013-01-28       Impact factor: 2.892

8.  The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice.

Authors:  Christopher M Mondie; Kelley A Vandergrift; Courtney L Wilson; Maria E Gulinello; E Todd Weber
Journal:  Behav Brain Res       Date:  2010-01-22       Impact factor: 3.332

9.  Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors.

Authors:  Stephanie A Reid-Arndt; Albert Yee; Michael C Perry; Catherine Hsieh
Journal:  J Psychosoc Oncol       Date:  2009

10.  Workplace support for employees with cancer.

Authors:  B Nowrouzi; N Lightfoot; K Cote; R Watson
Journal:  Curr Oncol       Date:  2009-09       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.